Home » Clinical Trials » Solid tumors » NCT07680257
NCT07680257

An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

Study Summary

An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.

Interested in this trial?

Submit an Inquiry

Interventions

SUV2208A cell injectionBIOLOGICAL
SUV2208A, DL1, 2 times, Day 0 and Day 28, IV
SUV2208ABIOLOGICAL
SUV2208A, DL2, 2 times, Day 0 and Day 28, IV
SUV2208ABIOLOGICAL
SUV2208A, DL3, 2 times, Day 0 and Day 28, IV

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital Of Anhui Medical UniversityHefeiAnhuiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: July 14, 2026